|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Of 63 patients with BRAF V600E-mutated mCRC and sufficient clinical data, 27 (42.9%) had right-sided colon tumors, 19 (30.2%) had left-sided colon tumors, and 17 (26.9%) had rectal tumors; 26 (41.3%) had peritoneal metastases, and 50 (79.4%) had distant lymph node metastases.
|
29037218 |
2017 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
dMMR and BRAF V600E mutations were identified in 31 of 208 (14.9%) and 23 of 211 (10.9%) tumors, respectively. dMMR was more commonly found in patients with primary colon tumors rather than rectal cancer (20.4% vs 7.6%, P =0.01), but there was no difference in MMR status between the right-sided and left-sided colon tumors (20.8% vs 34.6%, P = 0.24). dMMR was associated with early-stage rather than metastatic disease (17.3% vs 0%, P = 0.015).
|
25624727 |
2015 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
In conclusion, BRAF (p.V600E) colon tumors showed significant MEIS1 promoter methylation, which was associated with decreased MEIS1 gene expression.
|
24244575 |
2013 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
In conclusion, BRAF (p.V600E) colon tumors showed significant MEIS1 promoter methylation, which was associated with decreased MEIS1 gene expression.
|
24244575 |
2013 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.
|
22281684 |
2012 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.
|
22281684 |
2012 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Recently, it was shown that the oncogenic activation of BRAF, a member of the RAS/RAF family of kinases, by the V600E mutation is characteristic for sporadic colon tumors with microsatellite instability.
|
15782118 |
2005 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Recently, it was shown that the oncogenic activation of BRAF, a member of the RAS/RAF family of kinases, by the V600E mutation is characteristic for sporadic colon tumors with microsatellite instability.
|
15782118 |
2005 |
|
rs113488022
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Here, we examined the effect of colon tumor-associated B-Raf mutations within the kinase activation segment, including V599E, on extracellular signal-regulated kinase (Erk) and nuclear factor kappaB (NFkappaB) signaling, and on the transformation of NIH3T3 fibroblasts.
|
14678966 |
2003 |
|
rs121913377
|
|
|
0.770 |
GeneticVariation |
BEFREE |
Here, we examined the effect of colon tumor-associated B-Raf mutations within the kinase activation segment, including V599E, on extracellular signal-regulated kinase (Erk) and nuclear factor kappaB (NFkappaB) signaling, and on the transformation of NIH3T3 fibroblasts.
|
14678966 |
2003 |
|
rs397517132
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A CIMP(+)/BRAF(V600E)/MLH1(-) phenotype was found in 3/4 right colon tumors.
|
24503755 |
2014 |
|
rs397517132
|
|
|
0.020 |
GeneticVariation |
BEFREE |
To investigate the cause of the limited therapeutic effect of PLX4032 in BRAF(V600E) mutant colon tumours, here we performed an RNA-interference-based genetic screen in human cells to search for kinases whose knockdown synergizes with BRAF(V600E) inhibition.
|
22281684 |
2012 |
|
rs1463038513
|
|
|
0.020 |
GeneticVariation |
BEFREE |
From this descriptive study, it seems that the short-term risk for colonic polyps in I1307K APC mutation is low, primarily affecting patients with previously diagnosed colon tumors.
|
15733272 |
2005 |
|
rs1801155
|
|
|
0.020 |
GeneticVariation |
BEFREE |
From this descriptive study, it seems that the short-term risk for colonic polyps in I1307K APC mutation is low, primarily affecting patients with previously diagnosed colon tumors.
|
15733272 |
2005 |
|
rs2273535
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A genetic variant in STK15 T+91A (resulting in the amino acid substitution F31I) is associated with increased aneuploidy in colon tumors and cell transformation in vitro.
|
15802297 |
2005 |
|
rs2273535
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We identified a common genetic variant in STK15 (resulting in the amino acid substitution F31I) that is preferentially amplified and associated with the degree of aneuploidy in human colon tumors.
|
12881723 |
2003 |
|
rs1463038513
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We also compared the distribution and frequency of APC mutations from colon tumors that were positive and negative for the I1307K mutation.
|
9869603 |
1999 |
|
rs1801155
|
|
|
0.020 |
GeneticVariation |
BEFREE |
We also compared the distribution and frequency of APC mutations from colon tumors that were positive and negative for the I1307K mutation.
|
9869603 |
1999 |
|
rs112431538
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using NGS, the following mutations were detected: nonsense mutations in four tumor suppressor genes [APC R1114X (molecular argument that the cancer was a primary tumor of colon), TP53 R213X, RB1 E137X and FBWX7 R393X & S282X], mutations in three receptor tyrosine kinases (RET A919V of high transforming activity, EGFR E114K and FLT3 L601I) well known as oncogenes.
|
28730258 |
2017 |
|
rs121913331
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using NGS, the following mutations were detected: nonsense mutations in four tumor suppressor genes [APC R1114X (molecular argument that the cancer was a primary tumor of colon), TP53 R213X, RB1 E137X and FBWX7 R393X & S282X], mutations in three receptor tyrosine kinases (RET A919V of high transforming activity, EGFR E114K and FLT3 L601I) well known as oncogenes.
|
28730258 |
2017 |
|
rs1219568637
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Using NGS, the following mutations were detected: nonsense mutations in four tumor suppressor genes [APC R1114X (molecular argument that the cancer was a primary tumor of colon), TP53 R213X, RB1 E137X and FBWX7 R393X & S282X], mutations in three receptor tyrosine kinases (RET A919V of high transforming activity, EGFR E114K and FLT3 L601I) well known as oncogenes.
|
28730258 |
2017 |